Iannotta F, Fachinetti P, Fachinetti A, Pinotti G, Usellini L
J Endocrinol Invest. 1983 Oct;6(5):353-8. doi: 10.1007/BF03347615.
Nomifensine, TRH and insulin-induced hypoglycemia tests were carried out in 37 cases of hyperprolactinemia: 25 were due to PRL-secreting pituitary tumors, 6 cases to GH and PRL-secreting pituitary tumors and 6 to pituitary and suprasellar non secreting tumors. Nomifensine failed to suppress the serum PRL in all subjects and PRL responses to TRH and insulin-induced hypoglycemia were impaired in all patients, irrespective of the origin of hyperprolactinemia. The uniform pattern of PRL response to the above tests in patients with hyperprolactinemia of variable etiology suggests that none of them is specific for prolactinomas.
对37例高催乳素血症患者进行了去甲丙咪嗪、促甲状腺激素释放激素（TRH）和胰岛素诱发低血糖试验：其中25例由分泌催乳素的垂体瘤引起，6例由分泌生长激素和催乳素的垂体瘤引起，6例由垂体及鞍上无分泌功能的肿瘤引起。所有受试者服用去甲丙咪嗪后血清催乳素均未被抑制，且所有患者对TRH和胰岛素诱发低血糖的催乳素反应均受损，无论高催乳素血症的病因如何。不同病因的高催乳素血症患者对上述试验的催乳素反应模式一致，提示这些试验均对催乳素瘤无特异性。
